^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Cell Lung Cancer

    Related cancers:
    1d
    NRG-LU005: Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
    P3, N=544, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2029
    Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV
    2d
    Clinical Retrospective Study on the Role of Spleen-Invigorating and Qi-Supporting Therapy in Non-Small Cell Lung Cancer Immunotherapy and Construction of Survival Prediction Model. (PubMed, Biol Proced Online)
    The addition of TCM to PD‑1/PD‑L1 inhibitors prolongs PFS and OS in patients with stage IIIB-IV NSCLC. A survival prediction model based on routine clinical characteristics demonstrates predictive utility, offering a potential tool to inform clinical decision‑making.
    Retrospective data • Journal • IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • ALPL (Alkaline Phosphatase)
    |
    PD-L1 expression
    2d
    Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, Case Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=29 --> 14
    Enrollment closed • Enrollment change
    |
    Verzenio (abemaciclib)
    2d
    JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=119, Completed, Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • Loqtorzi (toripalimab-tpzi) • pemetrexed • etoposide IV • tifcemalimab (TAB004)
    2d
    DREAM: Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Sep 2028 | Trial primary completion date: Apr 2028 --> Sep 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab)
    3d
    Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan University
    New P2 trial
    |
    albumin-bound paclitaxel • etoposide IV • irinotecan • Zepzelca (lurbinectedin)
    3d
    7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI) (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, University of Missouri-Columbia | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer. (PubMed, BMC Cancer)
    The prognostic model developed in this study offers predictive value in estimating 12-month survival probability for SCLC patients, aiding clinicians in making more informed treatment decisions.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    PD-L1 expression • KIT expression
    |
    Rova-T (rovalpituzumab tesirine)
    3d
    Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer. (PubMed, Mol Cancer)
    This multimodal profiling analysis provides further insights into the biologic complexity of SCLC and highlights potential therapeutic vulnerabilities of distinct disease subtypes.
    Journal • IO biomarker
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    3d
    Development of a liquid overlay-based three-dimensional cell culture panel for drug screening applications. (PubMed, Sci Rep)
    Afterwards, the cytostatic and cytotoxic responses of these models to three targeted anti-PARP therapies, Olaparib, Rucaparib and Niraparib, were analyzed, revealing their sensitivity. These results demonstrated that our liquid overlay-based technique provides both a large cell culture panel, whatever the tissue type or pathological level, and an automated drug screening process that could lead to highly predictive efficacy results.
    Preclinical • Journal
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib)
    4d
    Debio 0123-SCLC-104: Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Debiopharm International SA | Trial completion date: Jul 2026 --> Feb 2026
    Trial completion date
    |
    carboplatin • etoposide IV • Debio 0123
    5d
    Small cell neuroendocrine carcinoma of the cervix: diagnostic challenges and emerging molecular insights†. (PubMed, J Pathol)
    This commentary emphasizes the pressing need for comprehensive diagnostics and further research to advance treatment strategies for this rare and challenging malignancy.
    Journal • IO biomarker
    |
    IFNA1 (Interferon Alpha 1)